Dose-Dependent Anti-Inflammatory and Neuroprotective Effects of an ανβ3 Integrin-Binding Peptide

Figure 8

Medium and high-dose C16 treatment decreased evidently the expression levels of GFAP both in spinal cord (a) and cerebral cortex (b), showed by Western blotting analysis. (c) The levels of GFAP expression revealed by Western blotting analysis at week 8 after immunization: ^aa𝑃<0.01 versus normal rats, ^a𝑃<0.05 versus normal rats, ^b𝑃<0.05 versus vehicle control rats at week 8 postimmunization group, ^c𝑃<0.05 versus 0.5 mg/per day C16 treated EAE rats at week 8 after immunization. The levels of GFAP expression were declined remarkably by late C16 application both in spinal cord (d) and cerebral cortex (e) compared with the vehicle control. (f) The levels of GFAP expression revealed by Western blotting analysis: ^a𝑃<0.05 versus normal rats, ^b𝑃<0.05 versus vehicle control rats, ^c𝑃<0.05 versus C16 treated EAE rats at week 2 postimmunization group and ^d𝑃<0.05 versus vehicle control rats at week 8 after immunization.